Overview

Detailed Summary

Bliss GVS Pharma Limited is a pharmaceutical company engaged in the global manufacturing, marketing, and export of pharmaceutical products, specializing in suppositories and pessaries.
The company holds a robust portfolio of over 250 products and operates five WHO-GMP, EU-GMP compliant facilities, with a significant market presence in Sub-Saharan Africa.
Bliss GVS focuses on research and development, with a dedicated center and a team of over 50 scientists recognized by the Government of India for advancements in formulations.
Despite facing regulatory hurdles in Ghana, the company resolved issues promptly to resume operations and maintain growth momentum.
Significant divestments have been made to streamline focus on core pharmaceutical operations, and a new multi-dosage facility in Maharashtra supports expanded product offerings.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 2,778 Cr
Volatility: High Risk
P/E Ratio: 23.3
Industry P/E: 32.3
PEG Ratio: 2.2
P/B Ratio: 2.5
52W High: 244.05
52W Low: 105.05

Sales CAGR

1Y: 5.13%
3Y: 1.59%
5Y: 8.59%
10Y: 8.23%

Profit CAGR

1Y: 10.64%
3Y: -9.38%
5Y: -5.67%
10Y: 0.56%

ROE

TTM: 9.68%
3Y: 7.66%
5Y: 6.70%
10Y: 9.92%

ROCE

TTM: 14.69%
3Y: 11.88%
5Y: 11.08%
10Y: 17.37%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
GUFICBIO		300.75	2,979 Cr	60.27	4.72	0.03	9.02	10.81	3.94
ORCHPHARMA		563.00	2,870 Cr	151.34	2.25	0.00	4.10	4.28	1.01
BLISSGVS		237.00	2,778 Cr	23.33	2.45	0.19	9.68	14.69	8.17
DCAL		162.10	2,647 Cr	21.41	0.42	0.00	2.14	3.12	1.07
UNICHEMLAB		346.00	2,623 Cr	8.28	1.08	0.00	5.98	6.30	8.29
IOLCP		94.05	2,612 Cr	23.81	1.49	0.90	6.62	9.15	4.80
NOVARTIND		994.40	2,373 Cr	25.24	3.06	2.60	13.75	17.93	10.43
Median: 7 Co.	—	300.75	2,647 Cr	23.81	2.25	0.03	6.62	9.15	4.80

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	212	201	198	184	218	210	198	207	244	218
Expenses	158	157	170	149	176	181	177	166	213	183
Operating Profit	54	44	28	34	41	30	21	41	32	35
OPM %	25.66	21.77	14.31	18.69	19.06	14.16	10.65	19.92	13.00	15.94
Other Income	13	5.42	-24	4.12	5.04	15	12	35	20	16
Interest	1.45	2.12	1.85	1.53	3.83	1.08	1.68	5.47	3.04	1.49
Depreciation	6.39	6.95	6.85	6.85	6.98	7.55	8.04	8.20	8.26	8.35
Profit Before Tax	59	40	-3.95	30	36	36	23	63	41	41
Tax %	27.21	27.40	-24.30	26.50	28.03	29.16	28.97	29.71	29.63	39.41
Net Profit	43	29	-4.91	22	26	26	17	44	29	25
EPS in Rs	3.93	2.57	-0.85	1.91	2.28	2.26	1.45	4.03	2.54	2.14

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	802	815	899	689	577	747	752	770	810	834
Expenses	596	618	741	566	471	629	634	620	683	700
Operating Profit	207	198	158	123	107	118	117	151	127	134
OPM %	25.76	24.25	17.54	17.89	18.48	15.83	15.61	19.56	15.65	16.04
Other Income	13	-7.66	38	26	20	-42	18	-0.46	36	68
Interest	20	23	4.41	7.57	5.51	4.74	10	6.91	8.12	12
Depreciation	20	21	8.94	13	17	17	19	26	29	31
Profit Before Tax	175	145	182	129	104	54	106	117	126	159
Tax %	35.76	38.97	30.37	26.14	28.96	57.30	27.66	30.20	28.16	29.10
Net Profit	113	89	127	95	74	23	77	82	90	113
EPS in Rs	10.10	7.15	11.70	9.19	6.35	1.39	6.64	7.04	7.90	10.16
Dividend Payout %	7.55	17.54	8.34	5.30	7.70	34.97	7.44	7.03	6.29	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	10	10	10	10	10	10	10	10	10	11
Reserves	402	476	526	636	725	798	808	873	957	1,040
Borrowings	100	213	112	97	109	122	109	102	100	88
Other Liabilities	249	323	212	162	183	147	181	171	147	162
Total Liabilities	762	1,023	860	905	1,027	1,077	1,109	1,157	1,214	1,301
Fixed Assets	225	304	136	145	241	234	281	378	369	405
CWIP	9.10	4.03	0.47	47	0.00	2.39	22	2.80	7.83	21
Investments	0.11	1.05	6.30	0.72	0.72	0.70	3.08	8.49	4.86	5.07
Other Assets	527	714	717	712	786	840	803	768	832	870
Total Assets	762	1,023	860	905	1,027	1,077	1,109	1,157	1,214	1,301

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	113	289	18	40	47	64	135	34	152	106
Cash from Investing Activity	-50	-231	50	-74	-48	-47	-93	-7.75	-133	-75
Cash from Financing Activity	-40	-10	-76	17	-6.30	-21	-24	-25	-21	-30
Net Cash Flow	23	48	-8.10	-17	-7.44	-3.82	19	1.62	-1.27	0.13

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	35.12%	35.06%	34.97%	34.97%	34.90%	34.82%	35.10%	35.29%	35.44%	35.39%	35.36%	35.36%
FIIs	16.50%	16.31%	15.35%	14.73%	13.25%	12.13%	13.51%	13.18%	12.65%	13.27%	14.54%	10.45%
DIIs	6.62%	6.61%	6.61%	6.59%	6.58%	6.57%	6.55%	6.55%	6.54%	5.98%	5.78%	5.04%
Public	41.75%	42.01%	43.08%	43.71%	45.27%	46.49%	44.84%	44.98%	45.36%	45.36%	44.32%	49.15%
Total Shareholders	42,182	43,234	40,758	45,157	44,737	52,937	49,558	49,517	46,707	44,461	43,380	44,874

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q1 FY20

Investor Presentation

Q4 FY19

Investor Presentation

Q3 FY19

Available on Pro Plan